10
IN THE NEWS
GENERAL SURGERY NEWS / OCTOBER 2021
Anatomy of a Lawsuit: Legal Pearls for the Wound Care Provider By CHASE DOYLE
W
ith more than 17,000 lawsuits for pressure injuries alone each year, legal action can be a very real consequence of practicing clinical medicine, especially for wound care providers. During the Symposium on Advanced Wound Care (SAWC) Spring meeting, Lee C. Ruotsi, MD, ABWMS, CWS-P, UHM, and Joyce Black, PhD, RN, discussed treatment and documentation strategies to reduce the risk for litigation, and to defend the treatment provided in a legal setting, should that become necessary. Dr. Black, a professor at the University of Nebraska Medical Center, in Waterloo, noted that to win a lawsuit, a patient’s lawyer must prove the following elements: • a professional duty owed to the patient; • breach of such duty; • injury caused by the breach; and • resulting damages, including wound, pain, disability and medical costs. An attorney may not file a lawsuit if they do not see proof of all four elements on initial review. According to Dr. Black, proper documentation is a critical piece in avoiding litigation. Typical consultation notes include history of the present illness, review of systems and the physical exam, followed by a diagnostic impression and treatment plan. If the patient’s condition is believed to be misclassified, the provider should document what the etiology is per the assessment and include supporting data. Failure to accurately identify the etiology of the wound can sometimes come at the demand of the administration. Because treatment of pressure injuries is not reimbursed, Dr. Black said, there may be pressure to instead diagnose the condition as a diabetic foot wound, for example. However, the treatment that follows is not the same, which could present serious problems during litigation. Another question that arises frequently in legal discussions is whether the condition was present on admission or unavoidable. Present-on-admission documentation allows for deep-tissue pressure injuries that are identified as evolving at the time of admission. For deep-tissue pressure injuries to be classified as “unavoidable,” said Dr. Black, the skin condition needs to be examined at the time of admission, but this is not limited to a 24-hour period, as these types of pressure injuries are not visible for 48 hours. Accurate assessment of risk, an appropriate plan of care and documentation of care are also required by the Centers for Medicare & Medicaid Services to establish a condition as unavoidable.
Costly Mistakes According to Dr. Black, the ability to speak to patients openly and honestly is an essential skill for a wound care provider and may even protect a provider from medical malpractice. When healing cannot occur, for example, it is imperative that the patient or family be “kept in the loop,” she said. “A family is going to be pretty upset if they thought a wound was minor or small and the patient ends up in the emergency
room,” Dr. Black said. “If a family is taking pictures of the wound, then you should be taking pictures of the wound because those photographs will come into play.” Although mistakes in the electronic health record rarely lead directly to patient harm, she added, those errors frequently result in lawsuits. Red flags in the EHR include changes in the record, gaps in time and information, improper wound measurements and incorrect wound terminology.
Finally, if a lawsuit goes to deposition or trial, the attitude of the provider can have a significant effect on the outcome. According to Dr. Black, a wound care provider should come across as caring and compassionate and express sincere concern about patient injuries. “Lawyers pick up on even the most subtle hints of apathy and will exploit them,” Dr. Black noted. “You must have [the] right attitude in your chart, in your deposition and at trial.”
on Rapid
.
Byfavo® VIQMQE^SPEQ -RXIRXMSREPP] HIWMKRIH EW E VETMH SRWIX VETMH SǻWIX sedative that may be used across many procedures and adult patient types. Rapid Onset
Š QMRYXIW XS SRWIX SJ WIHEXMZI IǻIGXW 3.0–3.5 minutes to peak sedation after initial 5 mg dose
Indication: Byfavo is a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Important Safety Information WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS • Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer Byfavo. • Administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation. • Byfavo has been associated with hypoxia, bradycardia, and hypotension. Continuously monitor vital signs during sedation and through the recovery period. • Resuscitative drugs, and age- and size-appropriate equipment for bag/ valve/mask assisted ventilation must be immediately available during administration of Byfavo. • Concomitant use of benzodiazepines with opioid analgesics may result in profound sedation, respiratory depression, coma, and death. The sedative effect of intravenous Byfavo can be accentuated by concomitantly administered CNS depressant medications, including other benzodiazepines and propofol. Continuously monitor patients for respiratory depression and depth of sedation.
Rapid 3ǻWIX
11.0-14.0 minutes to fully alert after last dose
Contraindication: Byfavo is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40. Personnel and Equipment for Monitoring and Resuscitation: See Boxed Warning. Consider the potential for worsened cardiorespiratory depression prior to using Byfavo concomitantly with other drugs that have the same potential (eg, opioid analgesics or other sedative-hypnotics). Administer supplemental oxygen to sedated patients through the recovery period. A EHQ]RGLD]HSLQH UHYHUVDO DJHQW ŴXPD]HQLO VKRXOG EH LPPHGLDWHO\ DYDLODEOH during administration of Byfavo. Risks From Concomitant Use With Opioid Analgesics and Other SedativeHypnotics: See Boxed Warning. Hypersensitivity Reactions: Byfavo contains dextran 40, which can cause hypersensitivity reactions, including rash, urticaria, pruritus, and anaphylaxis. Byfavo is contraindicated in patients with a history of severe hypersensitivity reaction to dextran 40 or products containing dextran 40. Neonatal Sedation: Use of benzodiazepines during the later stages of pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) in the neonate. Observe newborns for signs of sedation and manage accordingly. Pediatric Neurotoxicity: Published animal studies demonstrate that anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term FRJQLWLYH GHƓFLWV ZKHQ XVHG IRU ORQJHU WKDQ KRXUV 7KH FOLQLFDO VLJQLƓFDQFH of this is not clear. However, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through WKH ƓUVW VHYHUDO PRQWKV RI OLIH EXW PD\ H[WHQG RXW WR DSSUR[LPDWHO\ \HDUV RI
